After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
One of Indiana’s largest home health care providers, facing allegations that it put patients in immediate jeopardy, has agreed to be acquired by a competing company in a deal that could be worth as much as $3 million.
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
The founder of AIT Laboratories, along with his insurance companies and bank, will pay back more than $3 million to employees who bought the company from him six years ago at what the government said was an inflated price.